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cense.Abstract Introduction: Adipocytokines secreted by adipose tissue participate in bone metabolism;
leptin is one of the circulating peptides secreted by adipose tissue.
Aim of the work: To determine the serum levels of leptin in obese postmenopausal women in
order to correlate these levels with bone mineral density and bone biochemical markers to ﬁnd
out the role of leptin in bone metabolism.
Patients and methods: This was a cross-sectional study which included 37 obese postmenopausal
women with body mass index (BMI) >30 kg/m2. Thirty-seven lean postmenopausal women with
BMI <25 kg/m2 were included as control group. Serum leptin, bone speciﬁc alkaline phosphatase
(BAP), osteocalcin andurineC-telopeptide of type collagen (CTx)were assayed.Bonemineral density
(BMD) and soft tissue body composition were determined using dual energy X-ray absorptiometry.atology and Rehabilitation
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172 S.E. Ibrahim et al.Results: There was a statistically highly signiﬁcant increase in serum leptin levels in obese than
lean postmenopausal women (p< 0.0001). There was a highly signiﬁcant decrease in BMD of spine
and hip (p< 0.0001) in obese than lean postmenopausal women. After adjustment of fat mass, a
highly signiﬁcant positive correlation was found between leptin and BAP (r= 0.562, p< 0.0001),
a signiﬁcant positive correlation was found between leptin and each of osteocalcin and urine CTx
(r= 0.423, 0.456 respectively, p< 0.05) but there was no statistically signiﬁcant correlation between
leptin and BMD.
Conclusion: Our results support the hypothesis that leptin can act directly or indirectly on bone
remodeling by modulating osteoblast activities. Leptin was found to be associated with decreased
BMD at different sites of the body and was positively correlated with bone biochemical markers.
However, leptin did not come out to be an independent predictor of BMD whereas; fat mass was
found to have a role in bone metabolism in postmenopausal women. However these comparisons
of a single measurement of leptin with BMD, does not exclude possible long-term strong relation-
ships between leptin and BMD.
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Osteoporosis is a major public health problem in postmeno-
pausal women due to high risk of vertebral and hip fractures
as a result of low bone mineral density (BMD) [1]. It has long
been known that one of the best predictors of bone strength
and BMD is body mass; however, it is often debated whether
fat mass or lean mass (muscle) is a more important determinant
of BMD [2]. Lean mass is likely to have a local effect on bone
remodeling through mechanotransduction pathway. Peripheral
body fat appears to inﬂuence bone mass via secretion of numer-
ous factors that link body weight to bone density. Fat mass may
act as a peripheral site for conversion of androgens to estrogen,
serum estrogens are thought to be associated with decrease
BMD and increase risk of fractures in elderly women.
Leptin is the product of the obesity gene that is primarily re-
leased by adipose tissue, and is strongly correlated with fat
mass [3]. Obesity was thought to be a protective factor for oste-
oporosis, with an increased BMD and plasma leptin concentra-
tion [4]. Studies on the role of leptin in bone mass in women
have shown contradictory results [1]. The exact relationship be-
tween leptin and BMD however has not yet been elucidated.
Some of the studies observed no correlation between leptin
and bone mineral content, or between leptin and markers of
bone turnover [5]. Others found a signiﬁcant correlation be-
tween circulating leptin and BMD in postmenopausal women
[6]. Leptin that regulate appetite and energy expenditure might
be a potential mediator between body fat and bone [7].
The aim of this work was to determine the serum levels of
leptin in obese postmenopausal women in order to correlate
these levels with BMD and bone biochemical markers to ﬁnd
out the role of leptin in bone metabolism.
2. Patients and methods
This was a cross-sectional study that included 74 postmeno-
pausal women. They were divided into two groups, group 1
included 37 obese postmenopausal women (BMI < 30 kg/
m2) and group 2 included thirty-seven lean postmenopausal
women with BMI < 25 kg/m2. Both groups were matched as
regards age, sex and duration since menopause P5 years
duration. The patients were recruited from the outpatientclinic of Rheumatology and Rehabilitation and Internal
medicine departments in Ain Shams university hospitals.
Written informed consent was obtained from every patient
and control. The study was approved by Ain Shams medical
ethical committee.
Exclusion criteria included: Glucocorticoid use, smoking,
premature menopause, chronic disease (as renal, hepatic and
cardiac diseases), malignancy, diffuse intervertebral skeletal
hyperostosis (DISH), endocrinal diseases and the use of drugs
that affect bone metabolism like calcitonin and alendronate.
All patients were subjected to:
Full history taking including age, duration since meno-
pause, history of fertility, exposure to sun, dietary habits, exer-
cise level, activity of daily living (ADL) using the Lawton
questionnaire [8], history of previous fracture and family his-
tory of metabolic bone diseases.
 Thorough clinical examination.
 Anthropometric measurements including height, weight
and body mass index (BMI).
 Laboratory investigations: Blood samples for assaying of
calcium, phosphate, bone speciﬁc alkaline phosphatase
(BAP), osteocalcin and leptin were obtained between
9:00 and 9:30 am after night fasting. Second-void morn-
ing urine samples (10:00 am) were collected after night
fasting for determination of creatinine and degradation
products of C-telopeptide of type 1 collagen. Serum cal-
cium, phosphate and urine creatinine were measured
using standard conventional assays. BAP was measured
by an enzyme-linked immunosorbent assay (ELISA; Tan-
dem-MP Ostase, Beckman Coulter, USA). Osteocalcin
was measured by ELISA (N-MID Osteocalcin ELISA
kit product of Nordic Bioscience Diagnostics A/S, Herlev,
Denmark and provided by IBL Immuno-Bilogical Labo-
ratories Flughafenstrasse 52A, D-22335 Hamburg, Ger-
many). Urine C-telopeptide of type collagen (CTx) was
measured by ELISA (IBL Immuno-Bilogical Laboratories
Flughafenstrasse 52A, D-22335 Hamburg, Germany).
Serum leptin was measured using the DRG leptin ELISA
kit (Marburg, Germany).
 Radiological investigations:
1. Direct roentgenograms of the pelvic and lumbar regions
were done.
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the patients and control group using dual-energy
X-ray absorptiometry (DEXA) (GT-Lunar prodigy
Advance). Bone mineral density measurement was done
for the lower end of radius, for the lumbar vertebral lev-
els L2–L4 and for the neck of the femur. The results
were reported in g/cm2. The BMD report includes both
the raw bone mineral content (BMC) and the bone min-
eral density. This value was statistically applied in terms
of standard deviations (SD) in relation to the patient’s
age (Z score) or in relation to young adult mean (T
score). It is upon these latter results that osteoporosis
is diagnosed using the WHO deﬁnition [9].
3. Soft tissue body composition: Whole-body fat mass,
lean mass and percentage of fat mass (PFM) is the ratio
of fat mass divided by total body weight. To determine
body fat content, a whole body scans were performed
using a fan–beam model plus dual-energy X-ray absorp-
tiometry (DEXA) (GE Lunar prodigy Advance) [10].
 Statistics: Analysis of the data was done by IBM computer
using SPSS (statistical program for social science version
12). Mean and standard deviation (SD) were used to
describe quantitative variables. Number and percentage
were used for qualitative variables. Unpaired t-test was used
to compare quantitative variables, in parametric data
(SD < 50% mean). Correlation analysis (using Pearson’s
method) was to assess the strength of association between
two quantitative variables. The correlation coefﬁcient
denoted symbolically ‘‘r’’ deﬁnes the strength and directionTable 1 Comparison between patients and control group as regard
Parameter Obese
N= 37
Mean ± SD
Age (years) 57.35 ± 4.37
Age of menopause (years) 50.22 ± 2.38
Duration since menopause (years) 7.30 ± 2.92
ADL 7.14 ± 1.16
Body weight (kg) 86.54 ± 24.00
Height (cm) 152.51 ± 6.72
BMI (kg/m2) 37.41 ± 7.63
Total fat mass (kg) 41.68 ± 15.65
Lean mass(kg) 44.78 ± 8.98
PFM 47.04 ± 4.99
Leptin (ng/ml) 15.24 ± 4.79
Total BMC (g/cm2) 2.01 ± 0.39
BMD spine (g/cm2) 0.96 ± 0.14
T score spine 1.81 ± 1.51
Z score spine 0.99 ± 1.90
BMD hip (g/cm2) 0.639 ± 0.15
T score hip 1.81 ± 1.60
Z score hip 0.90 ± 1.38
BMD wrist (g/cm2) 0.83 0.34
T score wrist 1.59 ± 2.66
Z score wrist 0.66 ± 1.28
BAP (IU/Liter) 20.22 ± 3.48
Osteocalcin (ng/ml) 6.67 ± 0.91
Urine CTx (lg/mmol) 6.23 ± 0.75
ADL: activity of daily living, BMI: body mass index, PFM: percentage
BAP: bone speciﬁc alkaline phosphatase, CTx: C-telopeptide of type coof the linear relationship between two variables. Partial
Correlation procedure described the linear relationship
between two variables while adjusting for the effects of
one or more additional variables (p< 0.05: nonsigniﬁcant
(NS), p< 0.05: signiﬁcant (S), p< 0.001: highly signiﬁcant
(HS)).
3. Results
This study included 37 obese postmenopausal women
(BMI > 30 kg/m2) with mean age of 57.35 ± 4.37 years.
Thirty-seven postmenopausal women with BMI < 25 kg/m2
were included as control group with mean age of
56.56 ± 3.49 years.
There was a statistically highly signiﬁcant increase as re-
gards weight, BMI, PFM, total fat mass, lean mass, serum lep-
tin levels and urine CTx in obese postmenopausal women than
lean group (p< 0.0001). There was a statistically highly signif-
icant decrease as regards: height, total BMC, BMD of the
spine and hip, T score of spine, Z score of spine, Z score of
hip, T score of wrist and Z score of wrist in obese than nonob-
ese group (p< 0.0001). There was a statistically signiﬁcant de-
crease as regards T score of the hip and serum level of
osteocalcin in obese than lean group (p< 0.05). There was
no statistically signiﬁcant difference as regards age, age of
menopause, duration since menopause, ADL, BMD of the
wrist and BAP (Table 1).
On comparing leptin with different parameters in obese
group, we found a highly signiﬁcant positive correlation be-s clinical, laboratory and radiological investigations.
Nonobese
N= 37
Mean ± SD
t p Sig.
56.56 ± 3.49 .859 .3931 NS
49.94 ± 1.35 .047 .9626 NS
7.00 ± 2.70 .458 .647 NS
7.44 ± 0.92 1.232 .221 NS
63.22 ± 2.86 5.868 .0001 HS
162.61 ± 6.09 6.774 .0001 HS
23.67 ± 1.12 10.837 .0001 HS
22.41 ± 5.09 7.122 .001 HS
38.89 ± 3.57 3.707 .0004 HS
36.32 ± 7.08 7.528 .0001 HS
7.72 ± 1.18 9.272 .0001 HS
2.24 ± 0.23 3.09 .0028 HS
1.15 ± 0.13 6.049 .0001 HS
0.43 ± 1.12 4.464 .001 HS
0.73 ± 1.00 4.872 .001 HS
0.78 ± 0.14 4.106 .001 HS
-0.97 ± 1.10 2.631 .010 S
0.61 ± 1.12 5.167 .0001 HS
0.87 0.10 0.686 .494 NS
-0.16 ± 1.08 3.029 .0034 HS
0.41 ± 1.13 3.811 .0003 HS
20.94 ± 2.71 .992 .332 NS
7.17 ± 1.07 2.165 .033 S
5.71 ± 0.63 3.229 .0019 HS
fat mass, BMC: bone mineral content, BMD: bone mineral density,
llagen, HS: highly signiﬁcant, S: signiﬁcant, NS: nonsigniﬁcant.
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Figure 2 Linear regression curve showing highly signiﬁcant
positive correlation between leptin and osteocalcin (r= 0.787).
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Figure 1 Linear regression curve showing highly signiﬁcant
positive correlation between leptin and bone speciﬁc alkaline
phosphatase (r= 0.824).
174 S.E. Ibrahim et al.tween leptin and each of weight, BMI, total fat mass, PFM,
BAP (Fig. 1), osteocalcin (Fig. 2) and urine CTx (Fig. 3)
(p< 0.0001). There was a highly signiﬁcant negative correla-
tion between leptin and Z score of the spine and Z score of
the hip (p< 0.0001). A signiﬁcant negative correlation was
found between leptin and each of BMD of the spine, T score
of the spine, BMD of the hip, T score of the hip and Z score
of the wrist (p< 0.05). There was no signiﬁcant correlation be-
tween leptin and each of age of the patients, duration since
menopause, total BMC, BMD of the wrist and T score of
the wrist (p> 0.05) (Table 2).
Correlation between leptin, BMD and bone biochemical
markers after adjustment for fat mass showed that there was
a highly signiﬁcant positive correlation between leptin and
BAP (p< 0.0001). A signiﬁcant positive correlation was found
between leptin and each of osteocalcin and urine CTx
(p< 0.05) (Table 3).*CTx: C-telopeptide of type І c
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Figure 3 Linear regression curve showing highly signiﬁcant positive c
(r= 0.798).4. Discussion
Osteoporosis is a signiﬁcant cause of morbidity in older wo-
men. Leptin is a hormonal polypeptide secreted by adipocytes.
The aim of this work was to determine the serum levels of
leptin in obese postmenopausal women in order to correlate
these levels with bone mineral density and bone biochemical
markers to ﬁnd out the role of leptin in bone metabolism.
In our study, there were highly signiﬁcant decrease in total
BMC, BMD of the spine, BMD of the hip in obese than lean
postmenopausal women. There was a highly signiﬁcant in-
crease in urine CTx (a marker of bone resorption) and a signif-
icant increase in osteocalcin (a marker of bone formation and
turnover) in obese than lean postmenopausal women. Body
composition may be important in determining osteoporosis
risk [11]. Zhao et al. [7] conﬁrmed the inverse relationship be-
tween bone mass and fat after mechanical loading effects due
to increase body weight. A possible link between fat tissue
and bone tissue is the common stromal cell origin of both
osteoblast and adipocyte [12]. Stromal cells in the bone mar-
row can differentiate into one of several mature forms, includ-ollagen. 
eptin
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orrelation between leptin and urine C-telopeptide of type collagen
Table 2 Correlations between leptin and different parameters.
Parameter r p Sig.
Age .104 .538 NS
Duration since menopause (years) .114 .500 NS
Bodyweight (kg) .718 .0001 HS
BMI (kg) .902 .0001 HS
Total fat mass (kg) .832 .0001 HS
PFM .727 .0001 HS
Total BMC (g/cm2) .225 .181 NS
BMD spine (g/cm2) .399 .014 S
T score spine .475 .003 S
Z score spine .573 .0001 HS
BMD hip (g/cm2) .538 .001 S
T score hip .342 .038 S
Z score hip .636 .0001 HS
BMD wrist (g/cm2) .145 .391 NS
T score wrist .279 .094 NS
Z score wrist .453 .005 S
BAP (IU/Liter) .824 .0001 HS
Osteocalcin (ng/ml) .787 .0001 HS
Urine CTx (lg/mmol) .798 .0001 HS
ADL: activity of daily living, BMI: body mass index, PFM: per-
centage fat mass, BMC: bone mineral content, BMD: bone mineral
density, BAP: bone speciﬁc alkaline phosphatase, CTx: C-telo-
peptide of type collagen, HS: highly signiﬁcant, S: signiﬁcant, NS:
nonsigniﬁcant.
Table 3 Correlations between leptin, bone mineral density
and bone biochemical markers after adjustment for fat mass.
Parameter r p Sig.
BMD spine (g/cm2) .100 .562 NS
T score spine .228 .181 NS
Z score spine .263 .122 NS
BMD hip (g/cm2) .062 .719 NS
T score hip .078 .652 NS
Z score hip .150 .382 NS
BMD wrist (g/cm2) .067 .698 NS
T score wrist .136 .429 NS
Z score wrist .042 .807 NS
BAP (IU/Liter) .562 .0001 HS
Osteocalcin (ng/ml) .423 .01 S
Urine CTx (ug/mmol) .456 .005 S
BMD: bone mineral density, BAP: bone speciﬁc alkaline phos-
phatase, CTx: C-telopeptide of type collagen, HS: highly signiﬁ-
cant, S: signiﬁcant, NS: nonsigniﬁcant.
Serum leptin concentration, bone mineral density and bone biochemical markers 175ing osteoblast and adipocyte, under in vitro condition. The
peroxime proliferators-activated receptor pathway is the dom-
inant regulator of adipogenesis, it determines adipocyte differ-
entiation from mesenchymal progenitors and inhibits
osteoblast differentiation [13]. Fat tissue is metabolically ac-
tive, and hormonal factors may mediate an association of
PFM with bone mass. Fat may inﬂuence bone mass because
adipose tissue is the principle source of estrogen in postmeno-
pausal women through aromatization of androgens. Adipose
tissue itself secretes a number of cytokines, including inﬂam-
matory factors, such as tumor necrosis factor-alpha, and other
peptides like adiponectin that have receptors in bone cells and
are associated with variation in BMD among populations [14].
In contrast to our result Ravn et al. [15] reported that low BMIis an important risk factor for low bone mass in postmeno-
pausal women. Kuller et al. [16] concluded that overweight
or moderately obese postmenopausal women generally have
increased BMD relative to lean postmenopausal women.
In our results, leptin was higher in obese than lean post-
menopausal women. It was positively correlated with weight,
BMI, total fat mass and PFM. This was in accordance with
Pasco et al. [6] who reported that leptin correlated with weight,
BMI and fat mass. Bednarek-Tupikowska et al. [17] found that
serum leptin level was higher in obese premenopausal women
than lean premenopausal women. We found in our study no
signiﬁcant correlation between leptin and total BMC but there
was a signiﬁcant negative correlation between leptin and each
of BMD of the spine and BMD of the hip. These ﬁndings are
explained by the indirect role of leptin in the modulation of
bone mass through its effect at the pituitary gland. Animals
which lack leptin or leptin receptor have a massive increase
in bone mass despite the coexisting hypogonidism. The high
bone mass is not due to obesity since it is present in young
ob/ob mice before obesity develop. Moreover, leptin causes a
massive decrease in bone mass when infused into the third ven-
tricle of ob/ob mice. Based on these observations, it was pro-
posed that leptin may inhibit bone formation [18]. Leptin
deﬁcient ob/ob mice have decreased adrenergic tone, among
other neuro-endocrine abnormalities. Ducy et al. [19] proposed
that leptin exerts antiosteogenic effects by binding to its recep-
tors in hypothalamus, stimulating the release of noradrenaline
from sympathetic nerve ﬁbre projecting into bone. Noreadren-
aline is then thought to inhibit bone formation by binding to
B2 adrenergic receptors on osteoblasts [20]. Higher concentra-
tion of leptin actually induces apoptosis of bone marrow stro-
mal cells, decrease bone formation, and increase bone
resorption. Increased adipogenesis in bone could lead to very
high local concentrations of leptin in the bone marrow micro-
environment, contributing directly to bone loss [21].
After adjustment for fat mass, we found no signiﬁcant cor-
relation between serum leptin and total BMC and BMD. Our
result was similar to Champrosertyothin et al. [22] and Wu
et al. [5] who demonstrated that serum leptin concentrations
were not the signiﬁcant predictor for BMD. In addition, it
has been reported that leptin is a predictor of BMD only in
women prone to have a low BMD [23]. In contrast to our re-
sult, Yamauchi et al. [24] found that plasma leptin was posi-
tively correlated with BMD in postmenopausal women. Wu
et al. [5] found a negative correlation between leptin and
BMD in postmenopausal women. Leptin is produced in adipo-
cytes and is exponentially related to fat mass and not to lean
mass in nonobese women. BMI is calculated from both weight
which takes into account lean mass and height which shows
change with aging. Therefore, adjusting the association
between leptin and BMD for BMI is very likely less accurate
than adjusting for fat mass and may have altered the associa-
tion between leptin and BMD in this study [25]. However the
inclusion of obese women, who display a possible leptin resis-
tance [26] and wide range of serum leptin concentration, may
explain the leak of signiﬁcant correlation between leptin and
BMD in our study. The relationship between serum leptin
and BMD is ambiguous and these differing results may depend
on the race of the subjects used in the study [5].
There is highly signiﬁcant positive correlation between lep-
tin and each of BAP (a marker of bone formation) and OC
(a marker of bone formation and turnover) and urine CTx
176 S.E. Ibrahim et al.(a marker of bone resorption). After adjustment for fat mass,
there was still highly signiﬁcant positive correlation between
leptin and BAP, but there was only signiﬁcant positive corre-
lation with OC and urine CTx. In contrast to our result Blain
et al. [1] reported signiﬁcant positive correlation with BAP
and negative correlation with each of urine CTx and osteo-
calcin. After adjustment for fat mass, the negative correlation
remained only between leptin and urine CTx, and disap-
peared with markers of bone formation, suggesting an inhib-
iting effect of leptin on bone resorption. Wu et al. [5] found
no correlation between leptin and bone biochemical markers.
The effect of leptin on bone is complex. The relationship be-
tween leptin and both osteocalcin and BAP in the present
study illustrates the inﬂuence of leptin on bone formation
by enhancing osteoblastic differentiation and bone minerali-
zation. In vitro studies found that leptin can act directly on
bone marrow – derived mesenchymal stem cell to enhance
their differentiation to osteoblast and inhibits their differenti-
ation to adipocytes indicating that leptin inhibits bone
resorption and stimulates bone formation. The overall effect
of leptin on bone results from a balance between negative
central effects and positive direct peripheral effects, according
to serum leptin levels [27]. Leptin regulates bone formation
and bone resorption through sympathetic nervous system
(SNS) and CART. The sympathetic nervous system neuro-
transmitter, noradrenaline activates B2 adrenergic receptor
on osteoblast which activates two distinct molecular cascades.
One promotes RANKL expression which increases bone
resorption, and the other inhibits osteoblast proliferation
through the regulation of c-myc and cyclin-D expression
[28]. The action of leptin on bone resorption is not solely
dependent on SNS and led to the identiﬁcation of CART
as another molecule implicated in leptin’s action on bone
resorption [20]. Furthermore, pharmacological manipulation
of the signaling pathways activated by leptin may have signif-
icant potential for the treatment and prevention of bone loss.
Our results support the hypothesis that leptin can act di-
rectly or indirectly on bone remodeling by modulating osteo-
blast activities. Leptin was found to be associated with
decreased BMD at various sites of the body and was positively
correlated with bone biochemical markers. However, leptin did
not come out to be an independent predictor of BMD whereas;
fat mass was found to have a role in bone metabolism in post-
menopausal women. However these comparisons of a single
measurement of leptin with BMD, does not exclude possible
long-term strong relationships between leptin and BMD.References
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